By Heather Blumenthal Ostensibly, it’s a clinical trial of an immunotherapy for blood cancer patients with specific kinds of leukemia or lymphoma, for whom other treatments have not been successful. A better result could mean the difference between life and death for these patients; the importance of this trial for them cannot be overstated…. Read more »
Category: News
Where Are They Now: Marie-Laurence Tremblay
At BioCanRx, we are incredibly proud of our HQP and their dedication to cancer immunotherapy research. Whether they are working on viruses in the lab or examining the socioeconomic barriers to adopting certain treatments in Canada, each one plays a unique role in strengthening our network and expertise in immunotherapy. BioCanRx is invested in… Read more »
Dr. John Bell Interviewed on The Zoomer
Dr. John Bell, BioCanRx Scientific Director, joined panelists including Dr. Marcus Butler of the Princess Margaret Cancer Centre (and BioCanRx network investigator) to discuss the latest immunotherapy research and treatments on The Zoomer TV program. Click here to watch!
Intellectual capital is Canada’s most important natural resource
By KARIMAH ES SABAR Canada is often a leader in initiating creative programs for enabling innovation and commercialization, but it does not always stay the course long enough to benefit from their outcomes and economic benefits. COVID-19 is taxing the world’s health-care systems like never before, and Canada is no exception. During this… Read more »
World Cancer Day 2021
A Message from Dr. John Bell, Scientific Director and Dr. Stéphanie Michaud, President & CEO BioCanRx A future without cancer – it’s easy enough to imagine: A future without the immense burden of this disease on individuals, communities and health systems. A future without toxic and damaging treatment as the primary option… Read more »
CSA Member Profile: Paul O’Connell
CSA Member Profile Paul O’Connell of The Leukemia and Lymphoma Society of Canada & member of the BioCanRx – Cancer Stakeholder Alliance Working Group How did you get involved with the Leukemia & Lymphoma Society of Canada? What attracted you to the organization? Part of my Doctoral work at Dalhousie University in Nova… Read more »
The BioCanRx progression: A structure for success
By Heather Blumenthal When last this newsletter checked in with Michel Duval, he was working, with the help of a Catalyst grant from BioCanRx, on a new kind of immunotherapy to prevent relapses in children with leukemia who had had a hematopoietic stem cell transplant (HSCT). His project focused on stimulating their innate immune… Read more »
Where Are They Now: Parvez Vora
At BioCanRx, we are incredibly proud of our HQP and their dedication to cancer immunotherapy research. Whether they are working on viruses in the lab or examining the socioeconomic barriers to adopting certain treatments in Canada, each one plays a unique role in strengthening our network and expertise in immunotherapy. BioCanRx is invested in… Read more »
Where Are They Now: Laura Evgin
At BioCanRx, we are incredibly proud of our HQP and their dedication to cancer immunotherapy research. Whether they are working on viruses in the lab or examining the socioeconomic barriers to adopting certain treatments in Canada, each one plays a unique role in strengthening our network and expertise in immunotherapy. BioCanRx is invested in… Read more »
Protecting people with cancer from COVID-19
By Heather Blumenthal For people with cancer, COVID-19 poses a triple threat. First, their immune systems are suppressed, due both to the simple fact of having cancer, but also potentially as a result of cancer treatment, making them more vulnerable to severe illness should they be infected with the virus. Second, it’s hard… Read more »
